Molecular profiling of non-small cell lung cancer: of what value in clinical practice?
Future improvements in lung cancer survival are likely to come from delineating its putative oncogenic pathways. The development of microarray technology to perform thousands of simultaneous genetic experiments and the linking of this to clinical information is an imperative for refining our current treatments and developing new ones. This paper reviews the state of this research, describes a typical microarray experiment and the implications for diagnosis and treatment of non-small cell lung cancer.
Newnham
Genni M
GM
Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia.
Thomas
David M
DM
McLachlan
Sue Anne
SA
Wright
Gavin
G
Conron
Matthew
M
D014408:Biomarkers, Tumor / Q000235:genetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy; D016172:DNA Fingerprinting; D015195:Drug Design; D005260:Female; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D006801:Humans; D008297:Male; D020411:Oligonucleotide Array Sequence Analysis; D011379:Prognosis
D014408:Biomarkers, Tumor